Cotrimoxazole Prophylaxis for Toxoplasmosis
Authors: Eric Caumes
Journal: Annals of Internal Medicine (1993)

Letters1 March 1993Cotrimoxazole Prophylaxis for ToxoplasmosisEric Caumes, MD, Francois Lheriteau, MD, and Marc Gentilini, MDEric Caumes, MDSearch for more papers by this author, Francois Lheriteau, MDSearch for more papers by this author, and Marc Gentilini, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-118-5-199303010-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Carr and colleagues [1] reported the efficacy of low-dose cotrimoxazole as primary prophylaxis against toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome (AIDS). In their retrospective study, one double-strength tablet (trimethoprim, 160 mg, plus sulfamethoxazole, 800 mg), was given twice daily, 2 days per week. Another prospective study [2] showed a similar efficacy with one double-strength tablet daily. However, up to 90% of the Paris population is infected with Toxoplasma gondii compared with less than 50% in the United States [3]. Prospective European studies suggest that the cotrimoxazole dose can influence outcome [4, 5].We reviewed ...References1. Carr A, Tindall B, Brew BJ, Marriott DJ, Harkness JL, Penny R, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med. 1992; 117:106-11. Google Scholar2. Hardy D, Holzman R, Feinberg J, Finklestein D. Trimethoprim-sulfamethoxazole vs aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in AIDS patients: a prospective, randomized, controlled clinical trial (Abstract 018). In: Program and Abstracts of the third European Conference on Clinical Aspects and Treatment of HIV Infection, Paris, France; May 1992. Google Scholar3. McCabe R, Remington JS. Toxoplasmosis: the time has come. N Engl J Med. 1988; 318:313-5. Google Scholar4. Mallolas J, Zamora L, Gattel JM, Miro JM, Soriano E, Garcia San Miguel J. Primary prophylaxis for PCP and cerebral toxoplasmosis in HIV-infected patients: a randomized trial comparing cotrimoxazole, aerosolized pentamidine, and dapsone plus pyrimethamine (Abstract 035). In: Program and Abstracts of the third European Conference on Clinical Aspects and Treatment of HIV Infection, Paris, France; May 1992. Google Scholar5. Reynes J, Atoui N, Lassonnery N, et al. Cotrimoxazole in primary prophylaxis of cerebral toxoplasmosis in HIV-infected patients (Abstract P242) In: Program and Abstracts of the third European Conference on Clinical Aspects and Treatment of HIV Infection, Paris, France; May 1992. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByDaily cotrimoxazole prophylaxis in HIV infected childrenAcute toxoplasmosis in nonstem cell transplant patients with haematological malignancies: a study from a regional cancer institute in South IndiaCaractéristiques épidémiologiques des toxoplasmoses cérébrales chez 399 patients infectés par le VIH suivis entre 1983 et 1994Dapsone penetrates cerebrospinal fluid during Pneumocystis carinii pneumonia prophylaxisIV - Eléments de recommandations 1 March 1993Volume 118, Issue 5Page: 395KeywordsAIDSEncephalitisPneumocystisProphylaxisProspective studiesPyrimethamineRetrospective studiesToxoplasma gondiiToxoplasmosis Issue Published: 1 March 1993 CopyrightCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...